Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis

Bartholomew, 2019, Integration of Hepatitis C Treatment in a Primary care Federally Qualified Health Center; Philadelphia, Pennsylvania, 2015-2017, Infectious Diseases, 12 Bryant, 2019, Making sense of “side effects”: Counterpublic health in the era of direct-acting antivirals, International Journal of Drug Policy, 72, 77, 10.1016/j.drugpo.2019.06.002 Buller-Taylor, 2018, Reducing patient and provider knowledge gaps: An evaluation of a community informed hepatitis C online course, Patient Education and Counseling, 101, 1095, 10.1016/j.pec.2018.01.008 Childs, 2019, Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs, Harm Reduction Journal, 16, 1, 10.1186/s12954-019-0286-6 Douglass, 2018, Pathways to ensure universal and affordable access to hepatitis C treatment, BMC Medicine, 16, 175, 10.1186/s12916-018-1162-z Goodyear, 2020, Everybody living with a chronic disease is entitled to be cured”: Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs, International Journal of Drug Policy, 81, 10.1016/j.drugpo.2020.102766 Grebely, 2013, Breaking down the barriers to hepatitis C Virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels, Journal of Infectious Diseases, 207, S19, 10.1093/infdis/jis928 Harris, 2013, Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors, Harm Reduction Journal, 10, 10.1186/1477-7517-10-7 Hull, 2016, CIHR Canadian HIV trials network coinfection and concurrent diseases core research group: 2016 Updated Canadian HIV/hepatitis C adult guidelines for management and treatment, Canadian Journal of Infectious Diseases & Medical Microbiology (Journal Canadien Des) Maladies Infectieuses et de La Microbiologie Médicale (2016) Madden, 2018, Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?, PloS One, 13, 10.1371/journal.pone.0207226 Marshall, 2020, Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists - The practitioner experience, Drug and Alcohol Dependence, 206, 10.1016/j.drugalcdep.2019.107705 Mittal, 2019, HCV treatment access among Latinxs who inject drugs: Qualitative findings from Boston, Massachusetts, 2016, Harm Reduction Journal, 16, 44, 10.1186/s12954-019-0314-6 Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement, PLOS Medicine, 6, 10.1371/journal.pmed.1000097 Myles, 2011, Physicians’ attitudes and practice toward treating injection drug users infected with hepatitis C virus: Results from a National Specialist Survey in Canada [Original Article], Canadian Journal of Gastroenterology, 10.1155/2011/810108 2012 Nitulescu, 2019, Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals, International Journal of Drug Policy, 65, 41, 10.1016/j.drugpo.2018.08.012 Ouzzani, 2016, Rayyan—A web and mobile app for systematic reviews, Systematic Reviews, 5, 10.1186/s13643-016-0384-4 Paik, 2020, Changes in the global burden of chronic liver diseases from 2012 to 2017: The growing impact of NAFLD, Hepatology, 72, 1605, 10.1002/hep.31173 Pearce, 2019, Another thing to live for: Supporting HCV treatment and cure among Indigenous people impacted by substance use in Canadian cities, International Journal of Drug Policy, 74, 52, 10.1016/j.drugpo.2019.08.003 Platt, 2016, Prevalence and burden of HCV co-infection in people living with HIV: A global systematic review and meta-analysis, Lancet Infectious Diseases, 16, 797, 10.1016/S1473-3099(15)00485-5 Pourmarzi, 2020, Enablers and barriers for the provision of community-based HCV treatment: A case study of a real-world practice, Journal of Viral Hepatitis, 27, 484, 10.1111/jvh.13259 Richmond, 2018, Implementation of hepatitis C cure in Australia: One year on, Journal of Virus Eradication, 4, 115, 10.1016/S2055-6640(20)30254-5 Rogal, 2017, Primary care and hepatology provider-perceived barriers to and facilitators of hepatitis C treatment candidacy and adherence, Digestive Diseases and Sciences, 62, 1933, 10.1007/s10620-017-4608-9 Sacks-Davis, 2018, Linkage and retention in HCV care for HIV-infected populations: Early data from the DAA era, Journal of the International AIDS Society, 21, e25051, 10.1002/jia2.25051 Skeer, 2018, Hep C's like the common cold: Understanding barriers along the HCV care continuum among young people who inject drugs, Drug and Alcohol Dependence, 190, 246, 10.1016/j.drugalcdep.2018.06.013 Sutton, 2015, Qualitative research: Data collection, analysis, and management, Canadian Journal of Hospital Pharmacy, 68, 226, 10.4212/cjhp.v68i3.1456 Swan, 2010, Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: A qualitative exploration, AIDS Patient Care and STDs, 24, 753, 10.1089/apc.2010.0142 Thomas, 2019, Global elimination of chronic hepatitis, New England Journal of Medicine, 380, 2041, 10.1056/NEJMra1810477 Thomas, 2008, Methods for the thematic synthesis of qualitative research in systematic reviews, BMC Medical Research Methodology, 8, 45, 10.1186/1471-2288-8-45 Treloar, 2016, Multiple stigmas, shame and historical trauma compound the experience of Aboriginal Australians living with hepatitis C, Health Sociology Review, 25, 18, 10.1080/14461242.2015.1126187 Turan, 2019, Challenges and opportunities in examining and addressing intersectional stigma and health, BMC Medicine, 17, 7, 10.1186/s12916-018-1246-9 2018, 207 Wallace, 2018, Delivering the hepatitis C cure to Aboriginal people: Documenting the perspectives of one Aboriginal Health Service, Australian Journal of Primary Health, 24, 491, 10.1071/PY18024 2019 Yek, 2017, Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: A retrospective cohort study, BMC Medicine, 15, 10.1186/s12916-017-0969-3